Data & Platforms

This report provides a summary of the current spatial biology market landscape, as well as a forward-looking perspective of the spatial biology market from 2025 to 2030.

DeciBio conducted 11 interviews with academic researchers and biopharma executives to explore how advanced and next-generation proteomics tools have been adopted into research efforts today and how stakeholders expect their use of these tools to change in 2025

The sixth edition of this report takes a completely updated and comprehensive look at the SCA market. We assess the SCA market across 6 segments and 31 subsegments.

Next Generation Sequencing (NGS)*, having experienced significant stagnation from 2022 to 2024, is poised for a resurgence. We forecast that the ~$6.4B WW NGS manufacturer market (2024) will grow 9% p.a. to reach $8.3B in 2027.

The second edition of this report provides an overview of the digital pathology market from 2024 to 2029. The digital pathology market, as defined in this report, is comprised of revenue from instruments and software sold to clinical, academic, biopharma, and CRO customers, along with service revenues generated by CROs and reference labs.

Liquid biopsies (LBx), which, to-date, have been used largely for genomic profiling and therapy selection, are finding new applications throughout the patient journey and within pharma research. To help predict the future state of the market, we have developed an evaluation framework to identify and assess areas of growth within the liquid biopsy market.

DeciBio interviewed 10 biopharma leaders from the U.S. and EMEA to delve into the current usage, key applications, ROI, and unmet needs of AI/ML approaches in biopharma R&D, while also gathering insights on vendors used in the field.

The seventh edition of this report provides an overview of the life sciences research tools (LSRT) market from 2019 to 2027. LSRT companies offer instruments, reagents and services to academic, biopharma, applied market, and (non-IVD) clinical customers. While the LSRT space includes hundreds of companies, the market is relatively consolidated, with top vendors including Agilent, Becton Dickinson, Danaher, Illumina, Merck-EMD Millipore, and (most notably) Thermo Fisher representing the majority of sales; however, mid-size players (e.g., PacBio) and smaller emerging players (e.g., Element) are often growing more rapidly, and driving innovation.

The second edition of DeciBio's Clinical Oncology Biomarker Testing Market Report provides a summary of the current clinical oncology predictive and prognostic testing market landscape, as well as a forward-looking perspective of the market through 2028. Content includes a rigorous assessment of market size and growth, as well as key drivers, moderators, and trends related to predictive and prognostic biomarker testing in solid tumors.

DeciBio conducted 10 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care

This report provides an overview of the cell therapy R&D and manufacturing market, from 2023-2028. The cell therapy market, as defined in this report, is comprised of revenue from instruments, consumables, and software sold to academic, clinical, biopharma, CDMO and CRO customers, along with service revenues generated by CDMOs and CROs.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DeciBio conducted interviews with stakeholders to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

As part of an interview campaign to understand the impacts of European In Vitro Diagnostic Regulation (IVDR) on Clinical Labs, we spoke to the Global IVD Director at a Global Diagnostics Company.

As part of an interview campaign to understand the impacts of European In Vitro Diagnostic Regulation (IVDR) on Clinical Labs, we spoke to a Professor of Oncology and the Head of Pathology at an Italian Academic Medical Center.

As part of an interview campaign to understand the impacts of European In Vitro Diagnostic Regulation (IVDR) on Clinical Labs, we spoke to the Head of a Clinical Microbiology and Clinical Biomarker Platform at a French Academic Medical Center.

As part of an interview campaign to understand the impacts of European In Vitro Diagnostic Regulation (IVDR) on Clinical Labs, we spoke to a Professor of Molecular Medicine at a UK Academic Hospital.

As part of an interview campaign to understand the impacts of European In Vitro Diagnostic Regulation (IVDR) on Clinical Labs, we spoke to a Molecular Pathologist at a Spanish Academic Lab.

As part of an interview campaign to understand the impacts of European In Vitro Diagnostic Regulation (IVDR) on Clinical Labs, we spoke to a Head of Diagnostics at a German Academic Medical Center.

DeciBio conducted 12 interviews with U.S. clinicians and healthcare professionals to understand how blood-based EDx testing is being clinically adopted, to identify key regulatory and commercial barriers to broader use, to define the excitement around single and multi-cancer early detection (MCED) tests, and to collect vendor feedback from current users.

DeciBio conducted 9 interviews with experts at top Academic Medical Centers (AMC) and top biopharma stakeholders to better understand their perceptions and use of real-world data (RWD) at their organizations, as well as key RWD unmet needs and vendor perceptions.

DecBio conducted 10 interviews with clinical oncologists and KOLs at top biopharma to better understand their definitions and use of comprehensive genomic profiling (CGP) in the diagnosis and treatment of solid tumors, as well as key CGP pain points and vendor perceptions.

As part of an interview campaign to better understand comprehensive genomic profiling in the U.S., we interviewed an executive director of genomics at a top 10 pharma company.

As part of an interview campaign to better understand comprehensive genomic profiling in the U.S., we interviewed a medical oncologist and scientist at a northeast academic NCI comprehensive cancer center.

As part of an interview campaign to better understand comprehensive genomic profiling in the U.S., we interviewed a head of translational research at a top 20 pharma company.

As part of an interview campaign to better understand comprehensive genomic profiling in the U.S., we interviewed a medical oncologist at a medium-sized east-cast integrated health network.

As part of an interview campaign to better understand comprehensive genomic profiling in the U.S., we interviewed a medical oncologist at a specialty pacific medium integrated health network.

As part of an interview campaign to better understand comprehensive genomic profiling in the U.S., we interviewed a medical oncologist at a southwest community hospital.

As part of an interview campaign to better understand comprehensive genomic profiling in the U.S., we interviewed an executive director in translational oncology at a top 10 pharma company.

As part of an interview campaign to better understand comprehensive genomic profiling in the U.S., we interviewed a medical oncologist at a medium-sized midwestern integrated health network.

As part of an interview campaign to better understand comprehensive genomic profiling in the U.S., we interviewed a medical oncologist at an east coast integrated health network.

As part of an interview campaign to better understand comprehensive genomic profiling in the U.S., we interviewed a medical oncologist at a NCI comprehensive cancer center.

As part of an interview campaign to understand how biopharma utilizes and integrates digital and computational pathology tools, we interviewed a director of biomarker discovery at a small pharma company.

As part of an interview campaign to understand how biopharma utilizes and integrates digital and computational pathology tools, we interviewed a director of clinical project management at a top 20 pharma company.

As part of an interview campaign to understand how biopharma utilizes and integrates digital and computational pathology tools, we interviewed an executive director of translational medicine at a midsize biopharma company.

As part of an interview campaign to understand how biopharma utilizes and integrates digital and computational pathology tools, we interviewed an executive director of translational medicine at a top 20 pharma company.

As part of an interview campaign to understand how biopharma utilizes and integrates digital and computational pathology tools, we interviewed an executive vice president & CMO at a small pharma company.

As part of an interview campaign to understand how biopharma utilizes and integrates digital and computational pathology tools, we interviewed a head of diagnostics at a top 15 pharma company.

As part of an interview campaign to understand how biopharma utilizes and integrates digital and computational pathology tools, we interviewed a head of translational research at a top 20 pharma company.

As part of an interview campaign to understand how biopharma utilizes and integrates digital and computational pathology tools, we interviewed a principal scientist from a top 10 pharma company.

As part of an interview campaign to understand how biopharma utilizes and integrates digital and computational pathology tools, we interviewed a senior director of biomarker sciences at a top 15 pharma company.

As part of an interview campaign to understand how biopharma utilizes and integrates digital and computational pathology tools, we interviewed a senior principal clinical biomarker scientist at a top 10 pharma company.

DeciBio conducted 10 interviews with stakeholders at pharmaceutical companies to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

As part of an interview campaign to understand precision medicine opportunities in the women's health space, we interviewed a principal venture capitalist and clinician.

As part of an interview campaign to understand precision medicine opportunities in the women's health space, we interviewed a c-suite executive at a small-medium sized women's health pharma company.

As part of an interview campaign to understand precision medicine opportunities in the women's health space, we interviewed a c-suite executive at a small-medium sized women's health biotech company.

As part of an interview campaign to understand precision medicine opportunities in the women's health space, we interviewed an OB/GYN at a southwest integrated health network.

As part of an interview campaign to understand precision medicine opportunities in the women's health space, we interviewed a c-suite executive at a small-medium sized genomics biotech company.

As part of an interview campaign to understand precision medicine opportunities in the women's health space, we interviewed a board chair of a small-medium sized women's health biotech company.

As part of an interview campaign to understand precision medicine opportunities in the women's health space, we interviewed an assistant professor and OB/GYN at an academic medical center in the northeast.

As part of an interview campaign to understand precision medicine opportunities in the women's health space, we interviewed a medical affairs consultant and OB/GYN at a small-medium sized biotech, with a specialty in precision medicine.

As part of an interview campaign to understand precision medicine opportunities in the women's health space, we interviewed an OB/GYN at an integrated health network in the southeast.

As part of an interview campaign to understand precision medicine opportunities in the women's health space, we interviewed a product leader at a small-mid sized women's health biotech company.

As part of an interview campaign to understand precision medicine opportunities in the women's health space, we interviewed a marketing lead at a large global biotech with a specialty in reproductive health.

As part of an interview campaign to understand how pharma invests in technology supporting the development of precision medicines, we interviewed a senior director of biomarker sciences at a top 15 pharma company.

As part of an interview campaign to understand how pharma invests in technology supporting the development of precision medicines, we interviewed a head of diagnostics at a top 15 pharma company.

As part of an interview campaign to understand how pharma invests in technology supporting the development of precision medicines, we interviewed a head of translational research at a top 20 pharma company.

As part of an interview campaign to understand how pharma invests in technology supporting the development of precision medicines, we interviewed an executive director in translational medicine at a midsize biopharma company.

As part of an interview campaign to understand how pharma invests in technology supporting the development of precision medicines, we interviewed a senior vice president at a small precision medicine biopharma company.

As part of an interview campaign to understand how pharma invests in technology supporting the development of precision medicines, we interviewed an executive director of biomarker sciences at a top 20 pharma company.

As part of an interview campaign to understand how pharma invests in technology supporting the development of precision medicines, we interviewed an executive director in translational oncology at a top 10 pharma.

As part of an interview campaign to understand how pharma invests in technology supporting the development of precision medicines, we interviewed an executive director in translational medicine at a top 20 pharma company.

As part of an interview campaign to understand how pharma invests in technology supporting the development of precision medicines, we interviewed a head of drug discovery and development at a small biopharma company.

As part of an interview campaign to understand how pharma invests in technology supporting the development of precision medicines, we interviewed a head of precision medicine at a midsize pharma company.

As part of an interview campaign to understand current perceptions of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS, we interviewed a director of molecular pathology at a U.S. reference lab.

As part of an interview campaign to understand current perceptions of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS, we interviewed a director of oncology translational medicine at a top 10 pharma company.

As part of an interview campaign to understand current perceptions of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS, we interviewed a director of clinical project management at a top 30 pharma company.

As part of an interview campaign to understand current perceptions of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS, we interviewed a core laboratory director and professor of pathology at a U.S.-based AMC.

As part of an interview campaign to understand current perceptions of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS, we interviewed an executive director of translational medicine at a top 20 pharma.

As part of an interview campaign to understand current perceptions of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS, we interviewed a principal investigator at an ophthalmology center of excellence at an EU-based AMC.

As part of an interview campaign to understand current perceptions of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS, we interviewed a director of biomarkers at a global pharmaceutical CRO.

As part of an interview campaign to understand current perceptions of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS, we interviewed a senior director of oncology translational medicine at a top 10 pharma.

As part of an interview campaign to understand current perceptions of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS, we interviewed a director of spatial biology at a private U.S.-based children's research hospital.

As part of an interview campaign to understand current perceptions of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS, we interviewed a professor of computational genomics at an AMC in the U.S.

As part of an interview campaign to understand how advanced and next-generation proteomics tools have been adopted into research efforts, we interviewed a director of biomarkers at a national commercial reference lab.

As part of an interview campaign to understand how advanced and next-generation proteomics tools have been adopted into research efforts, we interviewed a head of diagnostics at a top 15 pharma.

As part of an interview campaign to understand how advanced and next-generation proteomics tools have been adopted into research efforts, we interviewed an associate professor of biomedicine at a western AMC research institute.

As part of an interview campaign to understand how advanced and next-generation proteomics tools have been adopted into research efforts, we interviewed a director of a cancer proteomics core at an east coast NCI comprehensive cancer center.

As part of an interview campaign to understand how advanced and next-generation proteomics tools have been adopted into research efforts, we interviewed a medical director of a cardiology department at a midwest AMC.

As part of an interview campaign to understand how advanced and next-generation proteomics tools have been adopted into research efforts, we interviewed a director of biomarker research at a medium-sized pharma company.

As part of an interview campaign to understand how advanced and next-generation proteomics tools have been adopted into research efforts, we interviewed an executive director of biomarker sciences at a top 20 pharma company.

As part of an interview campaign to understand how advanced and next-generation proteomics tools have been adopted into research efforts, we interviewed a head of cellular and molecular immunology at a NCI lab.

As part of an interview campaign to understand how advanced and next-generation proteomics tools have been adopted into research efforts, we interviewed a head of a proteomics core lab at a west coast research university.

As part of an interview campaign to understand how advanced and next-generation proteomics tools have been adopted into research efforts, we interviewed a professor of medicine in the medical oncology division at a southeastern AMC.

DeciBio conducted 11 interviews with OB/GYNs and KOLs in biotech / VC / pharma to explore key unmet needs / challenges, opportunities for precision medicine, and emerging players in women’s health.

DecBio conducted 10 interviews with KOLs at academic medical centers, pharmaceutical companies, reference labs, and CROs to better understand their perception of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS.

DeciBio conducted 11 interviews with KOLs at pharmaceutical companies to understand how pharma spends their money in support of therapeutic / precision medicine development initiatives today, and how these investments may change in the future